🏷️ LIMITED TIME OFFER: GET 20% OFF GRADE+ YEARLY SUBSCRIPTION →
Log in
HomeClass Notes1,200,000US530,000

BIOL 142 Lecture 28: Cell Signaling

82 views9 pages
bluemosquito338
30 Apr 2018
School
Emory University
Department
Biology
Course
BIOL 142
Professor
Patrick Cafferty

For unlimited access to Class Notes, a Class+ subscription is required.

1.#!"#$"%&'('&%)*%$)+,-)&%#+%'./0-1),#$%2'+'%0$,#(#,1%#+()&('3%-'2.&0,#)+%)*%,"'%&#*'%340+%
)*%5678%5)&'$.&'39%
8:% *'';<0$/%$)+,-)&%
=>
?:% ,-0+3&0,#)+0&%$)+,-)&%
@>
A:% ,-0+3$-#4,#)+0&%$)+,-)&%
B>
D)# posttranscriptional#control#
4.
C:% 4)3,,-0+3&0,#)+0&%$)+,-)&%
D>
7)+$);#+2%6783%0-'%#+()&(';%#+%-'2.&0,#+2%2'+'%'E4-'33#)+%
RNA#interference#$0+%-'3.&,%#+%-04#;%5678%;'2-0;0,#)+%#+%,"'%$1,)4&035>%
678%#+,'-*'-'+$'%G678#:%$0+%-'3.&,%#+%-04#;%5678%;'2-0;0,#)+%#+%,"'%$1,)4&035>%
678%#+,'-*'-'+$'%#+()&('3%34'$#*#$%56783%<'#+2%,0-2',';%<1%3#+2&'H%3,-0+;';%
microRNAs#GmiRNAs:>%
I@JH@BK%)*%0&&%0+#50&%0+;%4&0+,%2'+'3%0-'%-'2.&0,';%<1%5#6783>%
2.#!"#$"%)*%,"'%*)&&)L#+2%3,0,'5'+,3%$)--'$,&1%;'3$-#<'3%2'+'%-'2.&0,#)+%,"-).2"%678%
#+,'-*'-'+$'%G678#:9%
678%5)&'$.&'3%$0.3'%$&'0(02'%)*%;).<&'M%3,-0+;';%N78%)*%34'$#*#$%2'+'3>%
8>
microRNAs#(miRNAs)#associated#with#a#RISC#enzyme#bind#to#complementary#
mRNAs.#
B.
O"'%6PQA%'+R15'%<#+;3%,)%0+;%$&'0('3%;).<&'M3,-0+;';%56783>%
A>
678#%#+()&('3%<#+;#+2%)*%0%350&&%678%,)%0%,0-2',%2'+'%,)%#+0$,#(0,'%#,>%
N>
678#%L)-/3%<1%5#6783%0*,'-%4-)$'33#+2%<1%;#$'-%G$.,3%)**%"0#-4#+%&))4:
6PQA%L#&&%;'2-0;'%)+'%)*%,"'%@%5678%3,-0+;3
O"'%-'50#+#+2%3,-0+;%<#+;3%,)%,0-2',%$)54&'5'+,0-1%678
N)L+-'2.&0,'3%0$,#(#,1%)*%2'+'3S%'+$);#+2%,"'%2'+'3%#+%T.'3,#)+
6'2.&0,#+2%,"'%&#*',#5'%)*%0%4-),'#+%#3%0%L01%,)%$)+,-)&%#,3%0$,#)+3>%
U-),'#+3%#;'+,#*#';%*)-%<-'0/;)L+%0-'%)*,'+%&#+/';%,)%,"'%4)&14'4,#;'%Ubiquitin>%
7'';%,)%$)+,0#+%;'2-0;#+2%'+R15'3%3)%,"'1%;)+V,%;'2-0;'%'('-1,"#+2
U-),'03'3%#+%,"'%4-),'03)5'
O)%'+,'-%4-),'03)5'S%+'';%34'$#0&%0$$'33
○
O02%4-),'#+%L#,"%.<#T.#,#+%,"0,%*#,3%#+,)%0%4)-'%)+%,"'%4-),'03)5'
○
U-),'#+%L#&&%<'%;'&#('-';%,)%,"'%$'+,'-%)*%,"'%4-),'03)5'
○
O"'%protein–Ubiquitin#complex#,"'+%<#+;3%,)%0%$)54&'E%$0&&';% 0%proteasome>%F
O"'%4-),'#+%#3%$&'0(';%*-)5%,"'%Ubiquitin#0+;%,"-''%;#**'-'+,%proteases#digest#
the#protein>%
F
W('-0&&S%$'&&.&0-%4-),'#+%0$,#(#,#'3%;'4'+;%)+%-0,'3%)*%31+,"'3#3%0+;%-0,'3%)*%
;#2'3,#)+>%
F
X<#T.#,#+0,#)+%0+;%4-),'03)5'3%0-'%#+()&(';%#+%-'2.&0,#)+%,"'%&#*'340+%)*%
4-),'#+3%L#,"#+%,"'%$'&&
F
Y'0-+#+2%)<Z'$,#('3
!"#$%&'"()*"(+","%-.(/"$*-,&#/#(01($"..(#&+,-.&,+2(&,$.34&,+(3#"(01(#&+,-.(
)%-,#43$)&0,2(#"$0,4(/"##",+"%#2(-,4(#&+,-.(-/5.&1&$-)&0,(6&)*&,()*"($"..7(
87
90/5-%"()*"()60('%0-4($.-##"#(01(#&+,-.&,+(/0."$3."#(&,()*"('04:7(;%0-4.:(
$.-##&1&"4('-#"4(0,($*"/&$-.(/-<"357(=>?@(*:4%05*&.&$(0%(#/-..A*:4%05*0'&$B
C7
!"#$%&'"()*"(%0."(01()*"(#/-..(#&+,-.&,+(/0."$3."2(D&)%&$(0?&4"(=DEB2(&,()%&++"%&,+(
#/00)*(/3#$."(%".-?-)&0,(&,(-('.004FG"##".(6-..7(
H7
>?5.-&,()*"(/"$*-,&#/(01(-$)&0,(01(#)"%0&4(*0%/0,"#(350,()-%+")($"..#(3#&,+(
$0%)&#0.(-#(-,("?-/5."
I7
OL)%$)55.+#$0,#)+%313,'53
C+;)$-#+'%313,'5
[.50+%2-)L,"%")-5)+'%,"0,%'+,'-';%,"'%<&));%.3#+2%,"'%$#-$.&0,)-1%
313,'5%*)-%,-0+34)-,
○
F
7'-().3%313,'5
\03,'-
○
])-'%34'$#*#$
○
P+()&('%+'.-)+3%,"0,%'E,'+;%('-1%&)+2%4-)$'33'3%,)%-'0$"%34'$#*#$%,0-2',%
$'&&3
○
!"'+%3#2+0&%-'0$"'3%,"'%,'-5#+.3%)*%,"0,%$'&&S%0%+'.-),-0+35#,,'-%#3%
-'&'03';
○
F
?),"%"0('%$"'5#$0&3%0$,#+2%03%3#2+0&3
O'&&%$'&&3% ,)%;)%3)5',"#+2%0+;%2',%0%-'34)+3'%*-)5%,"'%+.$&'.3
○
Q#2+0&%#3%'E,'-+0&S%).,3#;'%,"'%$'&&
○
F
Outline:#Cell#Signaling#
[)L%$'&&3%$)55.+#$0,'^%3#2+0&%,-0+3;.$,#)+%0+;%@+;%5'33'+2'-3>%=>
Q50&&%3#2+0&#+2%5)&'$.&'3%'+,'-%,0-2',%$'&&3%0+;%<#+;%#+,-0$'&&.&0-%-'$'4,)-3>
7#,-#$_)E#;'%03%0%3#2+0&%0>
Q,'-)#;%")-5)+0&%$.'3%<>
@>
])3,%3#2+0&#+2%5)&'$.&'3%<#+;%$'&&_3.-*0$'%-'$'4,)-3>
`_4-),'#+%&#+/';%-'$'4,)-30>
P)+_$"0++'&%&#+/';%-'$'4,)-3%<>
C+R15'%&#+/';%-'$'4,)-3%$>
B>
87(J*"(+","%-.(/"$*-,&#/#(01($"..(#&+,-.&,+2(&,$.34&,+(3#"(01(#&+,-.()%-,#43$)&0,2(
#"$0,4(/"##",+"%#2(-,4(#&+,-.(-/5.&1&$-)&0,(6&)*&,()*"($"..7(
Signal#transduction##3%0+1%4-)$'33%<1%L"#$"%0%$'&&% $)+('-,3%)+'%/#+;%)*%3#2+0&%)-%
3,#5.&.3%#+,)%0+),"'->%
F
Signal#transduction##+()&('3%0%3'T.'+$'%)*%-'0$,#)+3%$0--#';%).,%<1%'+R15'3%
0+;%&#+/';%,"-).2"%3'$)+;%5'33'+2'-3
F
?#+;3%,)%0%-'$'4,)-%,)%3#2+0&%0+;%3,#5.&0,'3%0%-'34)+3'%#+%0%3#2+0&%,-0+3;.$,#)+%
40,"L01
W*,'+%+'';%,)%"044'+%#+%0%3,'4L#3'%50++'-
○
F
Q.$"%4-)$'33'3%,0/'%4&0$'%#+%03%&#,,&'%,#5'%03%0%5#&&#3'$)+;%)-%03%&)+2%03%0%*'L%
3'$)+;3>%
F
P+%50+1%,-0+3;.$,#)+%4-)$'33'3S%0+%#+$-'03#+2%+.5<'-%)*%'+R15'3%0+;%),"'-%
5)&'$.&'3%<'$)5'%'+202';%#+%,"'%'('+,3%,"0,%4-)$'';%*-)5%,"'%#+#,#0&%3,#5.&.3>%
O"'%$"0#+%)*%3,'43%#3%-'*'--';%,)%03%0%asignaling#cascade.”#
!"'-'%'0$"%'('+,%;'4'+;3%)+%,"'%4-'(#).3%'('+,
○
F
Second#messengers#0-'%5)&'$.&'3%,"0,%-'&01%3#2+0&3%-'$'#(';%0,%-'$'4,)-3%)+%,"'%$'&&%
3.-*0$'%
Q'$)+;%5'33'+2'-3%-'&01%3#2+0&3%b3.$"%03%,"'%0--#(0&%)*%4-),'#+%")-5)+'3S%
2-)L,"%*0$,)-3S%',$>%b,)%,0-2',%5)&'$.&'3%#+%,"'%$1,)3)&%0+;c)-%+.$&'.3>%
F
8;;#,#)+0&&1S%3'$)+;%5'33'+2'-3%3'-('%,)%amplify#the#strength#of#the#signal>%
7),%0%=^=%-'&0,#)+3"#43%)*%5)&'$.&'3%)*%3'$)+;%5'33'+2'-%0+;%5)&'$.&'3%
)*%3#2+0&
]0/'%0%&),%)*%5)&'$.&'3%)*%3'$)+;%5'33'+2'-%*)-%'('-1%)+'%3#2+0&
§
N)+'%3)%,"'%$'&&% 50/'3%0%-'34)+3'
§
A'&&%L#&&%4'-*)-5%0+%044-)4-#0,'%0$,#)+%;','-5#+';%<1%,"'%3#2+0&%#,%
-'$'#('3
§
○
F
CE054&'3%)*%3'$)+;%5'33'+2'-3%#+$&.;'%$1$&#$% +.$&'),#;'3%G'>2>S%$1$&#$%8]U%0+;%
$1$&#$%`]U:%0+;%A0&$#.5%#)+3%GA0@d:>%
7)+'%)*%,"'5%0-'%4-),'#+3
○
\)-53%3'$)+;%5'33'+2'-3
○
F
P54)-,0+,^
6'T.#-';%$)54)+'+,3%)*%40-,#$.&0-%40,"L013
○
854&#*1%3,-'+2,"%)*%3#2+0&3
○
F
C7(>?)%-$"..3.-%(#&+,-.(/0."$3."#(1-..(&,)0(0,"(01()60($.-##"#(
O"'%350&&'-%$&033%)*%3#2+0&3%$)+3#3,3%)*%5)&'$.&'3%,"0,%0-'%small%)-%hydrophobic%
'+).2"%,)%3&#4%'03#&1%,"-).2"%,"'%4&0350%5'5<-0+'%0+;%0$,#(0,'%#+,-0$'&&.&0-%
'+R15'3%)-%<#+;%,)%#+,-0$'&&.&0-% -'$'4,)-3%,)%-'2.&0,'%2'+'%'E4-'33#)+>%G*)-%
'>2>%e7#,-#$%WE#;'%0+;%A)-,#3)&:%
?'"0('%,"'%305'%L01%#+%3#2+0&#+2%40,"L0130>
U033%4&0350%5'5<-0+'%0+;%-'$'4,)-%,"0,%;','$,3%,"'#-%4-'3'+$'%#3%#+3#;'%
,"'%$'&&
<>
=>
O"'%&0-2'3,%$&033%)*%3#2+0&3%$)+3#3,3%)*%5)&'$.&'3%)oo%hydrophilic%,)%$-)33%,"'%
4&0350%5'5<-0+'%)*%,"'%,0-2',%$'&&>%O"'1%-'&1%)+%$'&&%3.-*0$'%-'$'4,)-3%,)%-'&01%
5'3302'3%#+,)%,"'%$'&&>%G*)-%'>2>%eP+3.&#+:%
P+3.&#+%#3%0%4-),'#+%")-5)+'%50;'%<1%,"'%40+$-'03
`)'3%,"-).2"%,"'%<&));%,)%$)55.+#$0,'%,"'%$'&&3% L"'+%,)%0<3)-<%
2&.$)3'%*-)5%,"'%<&));
#>
0>
8$,3%,"-).2"%$'&&%3.-*0$'%-'$'4,)-3<>
@>
H7(>,40)*".&-.($"..#(-%"()*"(#5"$&-.&K"42(1.-))","4("5&)*".&-.($"..#()*-)(.&,"("G"%:('.004(
G"##".
6';%<&));%$'&&%#+%0-,'-1%&'0;3%1).%,)%$)&&'$,%0%'+;),"'&#.5%$'&&3%,"0,%&#+'%,"'%
#+,'-#)-%)*%,"'%0-,'-1
N#05','-%#+*&.'+$'3%<&));%*&)L
○
A0+%$)+3,-#$,%35)),"%5.3$&'%)-%-'&0E'3
!"'+%-'&0E';S%,"'%#+,'-#)-%)*%,"'%0-,'-1%2',3%<#22'-%0+;%4-)5),'3%
<&));%*&)L
§
○
\#<-)<&03,%$'&&3%$-'0,'3%,#33.'%,"0,%")&;3%'('-1,"#+2%,)2',"'-
○
F
7#,-#$%)E#;'%G7W:%#3%0%;#33)&(';%203%,"0,%;#**.3'3%).,%)*%'+;),"'&#0&%$'&&3%f%'+,'-3%
+'#2"<)-#+2%35)),"%5.3$&'%$'&&3>%
P54)-,0+,%#+%;','-5#+#+2%,)%L"0,%;'2-''%).-%(03$.&0-%#3%$)+3,-#$,';%)-%-'&0E';F
7#,-#$%)E#;'%<#+;3%,)%,"'%'+R15'%Guanylyl#cyclase,#3,#5.&0,#+2%*)-50,#)+%)*%
$`]U%
X3'3%0-2#+#+'%,)%<-'0/%;)L+
○
F
The#gas#nitric#oxide#(NO)#causes#the#relaxation#of#smooth#muscles#of#the#blood#
vessels.#
Q50&&%3#2+0&%50;'%<1%'+;),"'&#.5%,)%$)55.+#$0,'%,)%35)),"%5.3$&'%0+;%
-'2.&0,'%<&));%*&)L
○
8$',1&$")&#+'%$0.3'3%#+$-'03';%A0@d%&'('&3%#+%,"'%'+;),"'&#0&%$'&&3S%L"#$"%
$0.3'3%,"'%0$,#(0,#)+%)*%NO#synthaseS%,"'%'+R15'%,"0,%50/'3%NO>%
X3'3%0-2#+#+'%03%0%3.<3,-0,'%,)%50/'%7W
§
A0,0<)&#$%-'0$,#)+%L"'-'%7W%#3%-'&'03';%*-)5%3.<3,-0,'%0-2#+#+'
§
○
NO#;#**.3'3%-04#;&1%*-)5%,"'%'+;),"'&#0&%$'&&3%,)%,"'%+'0-<1%35)),"%
5.3$&'%$'&&3>%
A0.3'3%#+$-'03'%)*%$`]U%$)+$'+,-0,#)+
§
○
P+%,"'%35)),"%5.3$&'%$'&&3S%NO#0$,#(0,'3%,"'%'+R15'%guanylyl#cyclaseS%
L"#$"%3,#5.&0,'3%,"'%*)-50,#)+%)*%$`]U>%
8$,#(0,'3%40,"L01%,"0,%$0.3'3%35)),"%5.3$&'%$'&&%,)%-'&0E
§
○
F
4.#[)L%;)'3%+#,-#$%)E#;'%G7W:%'+,'-%35)),"%5.3$&'%$'&&39%7W^%
$-)33'3%,"'%35)),"%5.3$&'%$'&&% 4&0350%5'5<-0+'%,"-).2"%#)+%$"0++'&3>%8>
$-)33'3%,"'%35)),"%5.3$&'%$'&&% 4&0350%5'5<-0+'%,"-).2"%$"0++'&3%$0&&';%
8T.04)-#+3>%
?>
diffuses#directly#across#the#smooth#muscle#cell#plasma#membrane.#C.
$0++),%'+,'-%35)),"%5.3$&'%$'&&3>%N>
7'';%,)%;'2-0;'%3'$)+;%5'33'+2'-
P*%$`]U%3,01';%,"'-'%*)-'('-S%1).%$0+V,%-'2.&0,'%<&));%*&)L%,)%,0-2',%,#33.'%0+;%
0&L013%"0('%0%"#2"%&'('&%)*%*&)L
F
Q5)),"%5.3$&'%L#&&%)+&1%<'%.3'*.&%#*%)+&1%3)5'%$)+;#,#)+3S%1).%$0+%4-)(#;'%
<&));%*&)L%,)%0%40-,#$.&0-%,#33.'%0+;%+),%,"'%0+),"'-
F
g#02-0%4-)5),'3%35)),"%5.3$&'%-'&0E0,#)+%#+%,"'%(03$.&0,.-'%
g#02-0%'+"0+$'3%,"'%'**'$,3%)*%7W%<1%inhibiting#the#enzyme#
Phosphodiesterase#(PDE)#,"0,%+)-50&&1%<-'0/3%;)L+%$`]US%4-)&)+2#+2%
,"'%7W%3#2+0&S%,".3%4-)&)+2#+2%4'+#&'%'-'$,#)+>%
UNC3%+)-50&&1%<-'0/%;)L+%3'$)+;%5'33'+2'-3
§
\)$.3'3%)+%0%-'4-);.$,#('%,#33.'
§
X3.0&&1%<-'0/3%;)L+%$`]U%#+%4'+0&%35)),"%5.3$&'3
§
○
W-#2#+0&&1%.3';%#+%4')4&'%L#,"%"'0-,%;#3'03'
P+0;('-,'+,%;#3$)('-1
§
○
P+"#<#,%UNC%0+;%4-)5),'%$`]U%3#2+0&#+2%0+;%<&));%*&)L
○
F
5.#P+;#(#;.0&3%4)33'33#+2%0%5.,0,#)+%#+%,"'%2'+'%'+$);#+2%,"'%'+R15'S%7#,-#$%WE#;'%
Q1+,"03'%G7WQ:%)('-4-);.$'%,"'%3#2+0&#+2%5)&'$.&'S%7#,-#$%WE#;'%G7W:%-'3.&,#+2%#+%&)L%
<&));%4-'33.-'>%W+%0%$'&&.&0-%&'('&S%L"#$"%)+'%)*%,"'%*)&&)L#+2%L).&;%<'%"'&4*.&%#+%
-';.$#+2%,"'%"0-5*.&%'**'$,3%)*%,"#3%7WQ%2'+'%5.,0,#)+9%
P+$-'03#+2%,"'%05).+,%)*%$1$&#$%2.0+)3#+'%5)+)4")34"0,'%G$`]U:%#+%35)),"%
5.3$&'%$'&&3>%
8&-'0;1%"0('%,))%5.$"%$`]U
○
8>
Increasing#the#activity#of#the#enzyme#phosphodiesterase#in#smooth#muscle#
cells.#
B.
P+$-'03#+2%,"'%8$',1&$")&#+'%3#2+0&%3'+,%,)%'+;),"'&#0&%$'&&3>%
8$',1&$")&#+'%3,#5.&0,'3%,"'%7W%31+,"03'%'+R15'%,"0,%L'%0&-'0;1%"0('%
,))%5.$"%)*
○
A>
P+"#<#,#+2%0$,#(0,#)+%)*%,"'%8$',1&$")&#+'%-'$'4,)-3%#+%'+;),"'&#0&%$'&&3>%
Q").&;%L)-/%<.,%,"'%#33.'%#3%,"0,%,"'%'+R15'%#3%<'#+2%*)-5';%#+%0+%
.+.3.0&%3,0,'%0+;%#3%)+%#+;'4'+;'+,%)*%0$',1&$")&#+'
○
P*%1).%-'5)('%,"'%0$',1&$")&#+'S%#,%L)+V,%0**'$,%,"'%)('-0$,#('%'+R15'
`'+'%5.,0,#)+%$0.3'3%,"'%.4-'2.&0,#)+S%+),%3)5',"#+2%'&3'%#+%,"'%
-'0$,#)+3
§
○
N>
N'$-'03#+2%,"'%0$,#(#,1%)*%,"'%'+R15'%4")34");#'3,'-03'%#+%'+;),"'&#0&%$'&&3>%C>
].,0,#)+%#+%7WQ%'E4-'33';%#+%'+;),"'&#0
7)-50&&1%4-);.$'3%7W%,)%3,#5.&0,'%35)),"%5.3$&'%$'&&%-'&0E0,#)+F
['-'S%"0('%0+%0&&'&'% ,"0,%$0.3'3%7W%,)%0&L013%<'%)+%0+;%#3%)('-4-);.$';F
!"'+%35)),"%5.3$&'%#3%0&L013%-'&0E';S%,"'-'V3%'--)+').3%<&));%*&)LF
X4-'2.&0,'%,"'%0$,#(#,1%)*%UNC%$'&&3%,)%<-'0/%;)L+%'E$'33%,)%$`]U%,)%$).+,'-0$,%
'**'$,%)*%,"#3%5.,0,#)+
F
I7(L:4%05*0'&$(#)"%0&4(*0%/0,"#($%0##()*"(5.-#/-(/"/'%-,"(01()*"()-%+")($"..
Q,'-)#;%")-5)+'3
N'-#(';%*-)5%$")&'3,'-)&%
○
A)-,#3)&%#+"#<#,3%,"'%#55.+'%313,'5
○
F
Q,'-)#;%")-5)+'3%0&&%4033%,"-).2"%,"'%4&0350%5'5<-0+'%)*%,"'%,0-2',%$'&&F
P+%,"'%$'&&S%,"'%")-5)+'3%<#+;%,)%0+;%0$,#(0,'%-'$'4,)-3%*).+;%#+%,"'%$1,)4&035%
)-%,"'%+.$&'.3
F
X4)+%0$,#(0,#)+S%,"'%")-5)+'%-'$'4,)-3%0-'%$040<&'%)*%-'2.&0,#+2%2'+'%
,-0+3$-#4,#)+
F
Cell$Signaling
])+;01S%84-#&%@BS%@J=h
=@^Ji%U]
Unlock document

This preview shows pages 1-3 of the document.
Unlock all 9 pages and 3 million more documents.

Already have an account? Log in
1.#!"#$"%&'('&%)*%$)+,-)&%#+%'./0-1),#$%2'+'%0$,#(#,1%#+()&('3%-'2.&0,#)+%)*%,"'%&#*'%340+%
)*%5678%5)&'$.&'39%
8:% *'';<0$/%$)+,-)&%=>
?:% ,-0+3&0,#)+0&%$)+,-)&%@>
A:% ,-0+3$-#4,#)+0&%$)+,-)&%B>
D)# posttranscriptional#control#4.
C:% 4)3,,-0+3&0,#)+0&%$)+,-)&%D>
7)+$);#+2%6783%0-'%#+()&(';%#+%-'2.&0,#+2%2'+'%'E4-'33#)+%
RNA#interference#$0+%-'3.&,%#+%-04#;%5678%;'2-0;0,#)+%#+%,"'%$1,)4&035>%F
678%#+,'-*'-'+$'%G678#:%$0+%-'3.&,%#+%-04#;%5678%;'2-0;0,#)+%#+%,"'%$1,)4&035>%F
678%#+,'-*'-'+$'%#+()&('3%34'$#*#$%56783%<'#+2%,0-2',';%<1%3#+2&'H%3,-0+;';%
microRNAs#GmiRNAs:>%
F
I@JH@BK%)*%0&&%0+#50&%0+;%4&0+,%2'+'3%0-'%-'2.&0,';%<1%5#6783>%F
2.#!"#$"%)*%,"'%*)&&)L#+2%3,0,'5'+,3%$)--'$,&1%;'3$-#<'3%2'+'%-'2.&0,#)+%,"-).2"%678%
#+,'-*'-'+$'%G678#:9%
678%5)&'$.&'3%$0.3'%$&'0(02'%)*%;).<&'M%3,-0+;';%N78%)*%34'$#*#$%2'+'3>%8>
microRNAs#(miRNAs)#associated#with#a#RISC#enzyme#bind#to#complementary#
mRNAs.#
B.
O"'%6PQA%'+R15'%<#+;3%,)%0+;%$&'0('3%;).<&'M3,-0+;';%56783>%A>
678#%#+()&('3%<#+;#+2%)*%0%350&&%678%,)%0%,0-2',%2'+'%,)%#+0$,#(0,'%#,>%N>
678#%L)-/3%<1%5#6783%0*,'-%4-)$'33#+2%<1%;#$'-%G$.,3%)**%"0#-4#+%&))4:
6PQA%L#&&%;'2-0;'%)+'%)*%,"'%@%5678%3,-0+;3F
O"'%-'50#+#+2%3,-0+;%<#+;3%,)%,0-2',%$)54&'5'+,0-1%678F
N)L+-'2.&0,'3%0$,#(#,1%)*%2'+'3S%'+$);#+2%,"'%2'+'3%#+%T.'3,#)+F
6'2.&0,#+2%,"'%&#*',#5'%)*%0%4-),'#+%#3%0%L01%,)%$)+,-)&%#,3%0$,#)+3>%
U-),'#+3%#;'+,#*#';%*)-%<-'0/;)L+%0-'%)*,'+%&#+/';%,)%,"'%4)&14'4,#;'%Ubiquitin>%F
7'';%,)%$)+,0#+%;'2-0;#+2%'+R15'3%3)%,"'1%;)+V,%;'2-0;'%'('-1,"#+2F
U-),'03'3%#+%,"'%4-),'03)5'
O)%'+,'-%4-),'03)5'S%+'';%34'$#0&%0$$'33
○
O02%4-),'#+%L#,"%.<#T.#,#+%,"0,%*#,3%#+,)%0%4)-'%)+%,"'%4-),'03)5'
○
U-),'#+%L#&&%<'%;'&#('-';%,)%,"'%$'+,'-%)*%,"'%4-),'03)5'
○
F
O"'%protein–Ubiquitin#complex#,"'+%<#+;3%,)%0%$)54&'E%$0&&';% 0%proteasome>%
O"'%4-),'#+%#3%$&'0(';%*-)5%,"'%Ubiquitin#0+;%,"-''%;#**'-'+,%proteases#digest#
the#protein>%
W('-0&&S%$'&&.&0-%4-),'#+%0$,#(#,#'3%;'4'+;%)+%-0,'3%)*%31+,"'3#3%0+;%-0,'3%)*%
;#2'3,#)+>%
X<#T.#,#+0,#)+%0+;%4-),'03)5'3%0-'%#+()&(';%#+%-'2.&0,#)+%,"'%&#*'340+%)*%
4-),'#+3%L#,"#+%,"'%$'&&
Y'0-+#+2%)<Z'$,#('3
!"#$%&'"()*"(+","%-.(/"$*-,&#/#(01($"..(#&+,-.&,+2(&,$.34&,+(3#"(01(#&+,-.(
)%-,#43$)&0,2(#"$0,4(/"##",+"%#2(-,4(#&+,-.(-/5.&1&$-)&0,(6&)*&,()*"($"..7(
87
90/5-%"()*"()60('%0-4($.-##"#(01(#&+,-.&,+(/0."$3."#(&,()*"('04:7(;%0-4.:(
$.-##&1&"4('-#"4(0,($*"/&$-.(/-<"357(=>?@(*:4%05*&.&$(0%(#/-..A*:4%05*0'&$B
C7
!"#$%&'"()*"(%0."(01()*"(#/-..(#&+,-.&,+(/0."$3."2(D&)%&$(0?&4"(=DEB2(&,()%&++"%&,+(
#/00)*(/3#$."(%".-?-)&0,(&,(-('.004FG"##".(6-..7(
H7
>?5.-&,()*"(/"$*-,&#/(01(-$)&0,(01(#)"%0&4(*0%/0,"#(350,()-%+")($"..#(3#&,+(
$0%)&#0.(-#(-,("?-/5."
I7
OL)%$)55.+#$0,#)+%313,'53
C+;)$-#+'%313,'5
[.50+%2-)L,"%")-5)+'%,"0,%'+,'-';%,"'%<&));%.3#+2%,"'%$#-$.&0,)-1%
313,'5%*)-%,-0+34)-,
○
7'-().3%313,'5
\03,'-
○
])-'%34'$#*#$
○
P+()&('%+'.-)+3%,"0,%'E,'+;%('-1%&)+2%4-)$'33'3%,)%-'0$"%34'$#*#$%,0-2',%
$'&&3
○
!"'+%3#2+0&%-'0$"'3%,"'%,'-5#+.3%)*%,"0,%$'&&S%0%+'.-),-0+35#,,'-%#3%
-'&'03';
○
?),"%"0('%$"'5#$0&3%0$,#+2%03%3#2+0&3
O'&&%$'&&3% ,)%;)%3)5',"#+2%0+;%2',%0%-'34)+3'%*-)5%,"'%+.$&'.3
○
Q#2+0&%#3%'E,'-+0&S%).,3#;'%,"'%$'&&
○
Outline:#Cell#Signaling#
[)L%$'&&3%$)55.+#$0,'^%3#2+0&%,-0+3;.$,#)+%0+;%@+;%5'33'+2'-3>%
=>
Q50&&%3#2+0&#+2%5)&'$.&'3%'+,'-%,0-2',%$'&&3%0+;%<#+;%#+,-0$'&&.&0-%-'$'4,)-3>
7#,-#$_)E#;'%03%0%3#2+0&%
0>
Q,'-)#;%")-5)+0&%$.'3%<>
@>
])3,%3#2+0&#+2%5)&'$.&'3%<#+;%$'&&_3.-*0$'%-'$'4,)-3>
`_4-),'#+%&#+/';%-'$'4,)-30>
P)+_$"0++'&%&#+/';%-'$'4,)-3%<>
C+R15'%&#+/';%-'$'4,)-3%$>
B>
87(J*"(+","%-.(/"$*-,&#/#(01($"..(#&+,-.&,+2(&,$.34&,+(3#"(01(#&+,-.()%-,#43$)&0,2(
#"$0,4(/"##",+"%#2(-,4(#&+,-.(-/5.&1&$-)&0,(6&)*&,()*"($"..7(
Signal#transduction##3%0+1%4-)$'33%<1%L"#$"%0%$'&&% $)+('-,3%)+'%/#+;%)*%3#2+0&%)-%
3,#5.&.3%#+,)%0+),"'->%
F
Signal#transduction##+()&('3%0%3'T.'+$'%)*%-'0$,#)+3%$0--#';%).,%<1%'+R15'3%
0+;%&#+/';%,"-).2"%3'$)+;%5'33'+2'-3
F
?#+;3%,)%0%-'$'4,)-%,)%3#2+0&%0+;%3,#5.&0,'3%0%-'34)+3'%#+%0%3#2+0&%,-0+3;.$,#)+%
40,"L01
W*,'+%+'';%,)%"044'+%#+%0%3,'4L#3'%50++'-
○
F
Q.$"%4-)$'33'3%,0/'%4&0$'%#+%03%&#,,&'%,#5'%03%0%5#&&#3'$)+;%)-%03%&)+2%03%0%*'L%
3'$)+;3>%
F
P+%50+1%,-0+3;.$,#)+%4-)$'33'3S%0+%#+$-'03#+2%+.5<'-%)*%'+R15'3%0+;%),"'-%
5)&'$.&'3%<'$)5'%'+202';%#+%,"'%'('+,3%,"0,%4-)$'';%*-)5%,"'%#+#,#0&%3,#5.&.3>%
O"'%$"0#+%)*%3,'43%#3%-'*'--';%,)%03%0%asignaling#cascade.”#
!"'-'%'0$"%'('+,%;'4'+;3%)+%,"'%4-'(#).3%'('+,
○
F
Second#messengers#0-'%5)&'$.&'3%,"0,%-'&01%3#2+0&3%-'$'#(';%0,%-'$'4,)-3%)+%,"'%$'&&%
3.-*0$'%
Q'$)+;%5'33'+2'-3%-'&01%3#2+0&3%b3.$"%03%,"'%0--#(0&%)*%4-),'#+%")-5)+'3S%
2-)L,"%*0$,)-3S%',$>%b,)%,0-2',%5)&'$.&'3%#+%,"'%$1,)3)&%0+;c)-%+.$&'.3>%
F
8;;#,#)+0&&1S%3'$)+;%5'33'+2'-3%3'-('%,)%amplify#the#strength#of#the#signal>%
7),%0%=^=%-'&0,#)+3"#43%)*%5)&'$.&'3%)*%3'$)+;%5'33'+2'-%0+;%5)&'$.&'3%
)*%3#2+0&
]0/'%0%&),%)*%5)&'$.&'3%)*%3'$)+;%5'33'+2'-%*)-%'('-1%)+'%3#2+0&
§
N)+'%3)%,"'%$'&&% 50/'3%0%-'34)+3'
§
A'&&%L#&&%4'-*)-5%0+%044-)4-#0,'%0$,#)+%;','-5#+';%<1%,"'%3#2+0&%#,%
-'$'#('3
§
○
F
CE054&'3%)*%3'$)+;%5'33'+2'-3%#+$&.;'%$1$&#$% +.$&'),#;'3%G'>2>S%$1$&#$%8]U%0+;%
$1$&#$%`]U:%0+;%A0&$#.5%#)+3%GA0@d:>%
7)+'%)*%,"'5%0-'%4-),'#+3
○
\)-53%3'$)+;%5'33'+2'-3
○
F
P54)-,0+,^
6'T.#-';%$)54)+'+,3%)*%40-,#$.&0-%40,"L013
○
854&#*1%3,-'+2,"%)*%3#2+0&3
○
F
C7(>?)%-$"..3.-%(#&+,-.(/0."$3."#(1-..(&,)0(0,"(01()60($.-##"#(
O"'%350&&'-%$&033%)*%3#2+0&3%$)+3#3,3%)*%5)&'$.&'3%,"0,%0-'%small%)-%hydrophobic%
'+).2"%,)%3&#4%'03#&1%,"-).2"%,"'%4&0350%5'5<-0+'%0+;%0$,#(0,'%#+,-0$'&&.&0-%
'+R15'3%)-%<#+;%,)%#+,-0$'&&.&0-% -'$'4,)-3%,)%-'2.&0,'%2'+'%'E4-'33#)+>%G*)-%
'>2>%e7#,-#$%WE#;'%0+;%A)-,#3)&:%
?'"0('%,"'%305'%L01%#+%3#2+0&#+2%40,"L0130>
U033%4&0350%5'5<-0+'%0+;%-'$'4,)-%,"0,%;','$,3%,"'#-%4-'3'+$'%#3%#+3#;'%
,"'%$'&&
<>
=>
O"'%&0-2'3,%$&033%)*%3#2+0&3%$)+3#3,3%)*%5)&'$.&'3%)oo%hydrophilic%,)%$-)33%,"'%
4&0350%5'5<-0+'%)*%,"'%,0-2',%$'&&>%O"'1%-'&1%)+%$'&&%3.-*0$'%-'$'4,)-3%,)%-'&01%
5'3302'3%#+,)%,"'%$'&&>%G*)-%'>2>%eP+3.&#+:%
P+3.&#+%#3%0%4-),'#+%")-5)+'%50;'%<1%,"'%40+$-'03
`)'3%,"-).2"%,"'%<&));%,)%$)55.+#$0,'%,"'%$'&&3% L"'+%,)%0<3)-<%
2&.$)3'%*-)5%,"'%<&));
#>
0>
8$,3%,"-).2"%$'&&%3.-*0$'%-'$'4,)-3<>
@>
H7(>,40)*".&-.($"..#(-%"()*"(#5"$&-.&K"42(1.-))","4("5&)*".&-.($"..#()*-)(.&,"("G"%:('.004(
G"##".
6';%<&));%$'&&%#+%0-,'-1%&'0;3%1).%,)%$)&&'$,%0%'+;),"'&#.5%$'&&3%,"0,%&#+'%,"'%
#+,'-#)-%)*%,"'%0-,'-1
N#05','-%#+*&.'+$'3%<&));%*&)L
○
A0+%$)+3,-#$,%35)),"%5.3$&'%)-%-'&0E'3
!"'+%-'&0E';S%,"'%#+,'-#)-%)*%,"'%0-,'-1%2',3%<#22'-%0+;%4-)5),'3%
<&));%*&)L
§
○
\#<-)<&03,%$'&&3%$-'0,'3%,#33.'%,"0,%")&;3%'('-1,"#+2%,)2',"'-
○
F
7#,-#$%)E#;'%G7W:%#3%0%;#33)&(';%203%,"0,%;#**.3'3%).,%)*%'+;),"'&#0&%$'&&3%f%'+,'-3%
+'#2"<)-#+2%35)),"%5.3$&'%$'&&3>%
P54)-,0+,%#+%;','-5#+#+2%,)%L"0,%;'2-''%).-%(03$.&0-%#3%$)+3,-#$,';%)-%-'&0E';F
7#,-#$%)E#;'%<#+;3%,)%,"'%'+R15'%Guanylyl#cyclase,#3,#5.&0,#+2%*)-50,#)+%)*%
$`]U%
X3'3%0-2#+#+'%,)%<-'0/%;)L+
○
F
The#gas#nitric#oxide#(NO)#causes#the#relaxation#of#smooth#muscles#of#the#blood#
vessels.#
Q50&&%3#2+0&%50;'%<1%'+;),"'&#.5%,)%$)55.+#$0,'%,)%35)),"%5.3$&'%0+;%
-'2.&0,'%<&));%*&)L
○
8$',1&$")&#+'%$0.3'3%#+$-'03';%A0@d%&'('&3%#+%,"'%'+;),"'&#0&%$'&&3S%L"#$"%
$0.3'3%,"'%0$,#(0,#)+%)*%NO#synthaseS%,"'%'+R15'%,"0,%50/'3%NO>%
X3'3%0-2#+#+'%03%0%3.<3,-0,'%,)%50/'%7W
§
A0,0<)&#$%-'0$,#)+%L"'-'%7W%#3%-'&'03';%*-)5%3.<3,-0,'%0-2#+#+'
§
○
NO#;#**.3'3%-04#;&1%*-)5%,"'%'+;),"'&#0&%$'&&3%,)%,"'%+'0-<1%35)),"%
5.3$&'%$'&&3>%
A0.3'3%#+$-'03'%)*%$`]U%$)+$'+,-0,#)+
§
○
P+%,"'%35)),"%5.3$&'%$'&&3S%NO#0$,#(0,'3%,"'%'+R15'%guanylyl#cyclaseS%
L"#$"%3,#5.&0,'3%,"'%*)-50,#)+%)*%$`]U>%
8$,#(0,'3%40,"L01%,"0,%$0.3'3%35)),"%5.3$&'%$'&&%,)%-'&0E
§
○
F
4.#[)L%;)'3%+#,-#$%)E#;'%G7W:%'+,'-%35)),"%5.3$&'%$'&&39%7W^%
$-)33'3%,"'%35)),"%5.3$&'%$'&&% 4&0350%5'5<-0+'%,"-).2"%#)+%$"0++'&3>%8>
$-)33'3%,"'%35)),"%5.3$&'%$'&&% 4&0350%5'5<-0+'%,"-).2"%$"0++'&3%$0&&';%
8T.04)-#+3>%
?>
diffuses#directly#across#the#smooth#muscle#cell#plasma#membrane.#C.
$0++),%'+,'-%35)),"%5.3$&'%$'&&3>%N>
7'';%,)%;'2-0;'%3'$)+;%5'33'+2'-
P*%$`]U%3,01';%,"'-'%*)-'('-S%1).%$0+V,%-'2.&0,'%<&));%*&)L%,)%,0-2',%,#33.'%0+;%
0&L013%"0('%0%"#2"%&'('&%)*%*&)L
F
Q5)),"%5.3$&'%L#&&%)+&1%<'%.3'*.&%#*%)+&1%3)5'%$)+;#,#)+3S%1).%$0+%4-)(#;'%
<&));%*&)L%,)%0%40-,#$.&0-%,#33.'%0+;%+),%,"'%0+),"'-
F
g#02-0%4-)5),'3%35)),"%5.3$&'%-'&0E0,#)+%#+%,"'%(03$.&0,.-'%
g#02-0%'+"0+$'3%,"'%'**'$,3%)*%7W%<1%inhibiting#the#enzyme#
Phosphodiesterase#(PDE)#,"0,%+)-50&&1%<-'0/3%;)L+%$`]US%4-)&)+2#+2%
,"'%7W%3#2+0&S%,".3%4-)&)+2#+2%4'+#&'%'-'$,#)+>%
UNC3%+)-50&&1%<-'0/%;)L+%3'$)+;%5'33'+2'-3
§
\)$.3'3%)+%0%-'4-);.$,#('%,#33.'
§
X3.0&&1%<-'0/3%;)L+%$`]U%#+%4'+0&%35)),"%5.3$&'3
§
○
W-#2#+0&&1%.3';%#+%4')4&'%L#,"%"'0-,%;#3'03'
P+0;('-,'+,%;#3$)('-1
§
○
P+"#<#,%UNC%0+;%4-)5),'%$`]U%3#2+0&#+2%0+;%<&));%*&)L
○
F
5.#P+;#(#;.0&3%4)33'33#+2%0%5.,0,#)+%#+%,"'%2'+'%'+$);#+2%,"'%'+R15'S%7#,-#$%WE#;'%
Q1+,"03'%G7WQ:%)('-4-);.$'%,"'%3#2+0&#+2%5)&'$.&'S%7#,-#$%WE#;'%G7W:%-'3.&,#+2%#+%&)L%
<&));%4-'33.-'>%W+%0%$'&&.&0-%&'('&S%L"#$"%)+'%)*%,"'%*)&&)L#+2%L).&;%<'%"'&4*.&%#+%
-';.$#+2%,"'%"0-5*.&%'**'$,3%)*%,"#3%7WQ%2'+'%5.,0,#)+9%
P+$-'03#+2%,"'%05).+,%)*%$1$&#$%2.0+)3#+'%5)+)4")34"0,'%G$`]U:%#+%35)),"%
5.3$&'%$'&&3>%
8&-'0;1%"0('%,))%5.$"%$`]U
○
8>
Increasing#the#activity#of#the#enzyme#phosphodiesterase#in#smooth#muscle#
cells.#
B.
P+$-'03#+2%,"'%8$',1&$")&#+'%3#2+0&%3'+,%,)%'+;),"'&#0&%$'&&3>%
8$',1&$")&#+'%3,#5.&0,'3%,"'%7W%31+,"03'%'+R15'%,"0,%L'%0&-'0;1%"0('%
,))%5.$"%)*
○
A>
P+"#<#,#+2%0$,#(0,#)+%)*%,"'%8$',1&$")&#+'%-'$'4,)-3%#+%'+;),"'&#0&%$'&&3>%
Q").&;%L)-/%<.,%,"'%#33.'%#3%,"0,%,"'%'+R15'%#3%<'#+2%*)-5';%#+%0+%
.+.3.0&%3,0,'%0+;%#3%)+%#+;'4'+;'+,%)*%0$',1&$")&#+'
○
P*%1).%-'5)('%,"'%0$',1&$")&#+'S%#,%L)+V,%0**'$,%,"'%)('-0$,#('%'+R15'
`'+'%5.,0,#)+%$0.3'3%,"'%.4-'2.&0,#)+S%+),%3)5',"#+2%'&3'%#+%,"'%
-'0$,#)+3
§
○
N>
N'$-'03#+2%,"'%0$,#(#,1%)*%,"'%'+R15'%4")34");#'3,'-03'%#+%'+;),"'&#0&%$'&&3>%C>
].,0,#)+%#+%7WQ%'E4-'33';%#+%'+;),"'&#0
7)-50&&1%4-);.$'3%7W%,)%3,#5.&0,'%35)),"%5.3$&'%$'&&%-'&0E0,#)+F
['-'S%"0('%0+%0&&'&'% ,"0,%$0.3'3%7W%,)%0&L013%<'%)+%0+;%#3%)('-4-);.$';F
!"'+%35)),"%5.3$&'%#3%0&L013%-'&0E';S%,"'-'V3%'--)+').3%<&));%*&)LF
X4-'2.&0,'%,"'%0$,#(#,1%)*%UNC%$'&&3%,)%<-'0/%;)L+%'E$'33%,)%$`]U%,)%$).+,'-0$,%
'**'$,%)*%,"#3%5.,0,#)+
F
I7(L:4%05*0'&$(#)"%0&4(*0%/0,"#($%0##()*"(5.-#/-(/"/'%-,"(01()*"()-%+")($"..
Q,'-)#;%")-5)+'3
N'-#(';%*-)5%$")&'3,'-)&%
○
A)-,#3)&%#+"#<#,3%,"'%#55.+'%313,'5
○
F
Q,'-)#;%")-5)+'3%0&&%4033%,"-).2"%,"'%4&0350%5'5<-0+'%)*%,"'%,0-2',%$'&&F
P+%,"'%$'&&S%,"'%")-5)+'3%<#+;%,)%0+;%0$,#(0,'%-'$'4,)-3%*).+;%#+%,"'%$1,)4&035%
)-%,"'%+.$&'.3
F
X4)+%0$,#(0,#)+S%,"'%")-5)+'%-'$'4,)-3%0-'%$040<&'%)*%-'2.&0,#+2%2'+'%
,-0+3$-#4,#)+
F
Cell$Signaling
])+;01S%84-#&%@BS%@J=h =@^Ji%U]
Unlock document

This preview shows pages 1-3 of the document.
Unlock all 9 pages and 3 million more documents.

Already have an account? Log in
1.#!"#$"%&'('&%)*%$)+,-)&%#+%'./0-1),#$%2'+'%0$,#(#,1%#+()&('3%-'2.&0,#)+%)*%,"'%&#*'%340+%
)*%5678%5)&'$.&'39%
8:% *'';<0$/%$)+,-)&%=>
?:% ,-0+3&0,#)+0&%$)+,-)&%@>
A:% ,-0+3$-#4,#)+0&%$)+,-)&%B>
D)# posttranscriptional#control#4.
C:% 4)3,,-0+3&0,#)+0&%$)+,-)&%D>
7)+$);#+2%6783%0-'%#+()&(';%#+%-'2.&0,#+2%2'+'%'E4-'33#)+%
RNA#interference#$0+%-'3.&,%#+%-04#;%5678%;'2-0;0,#)+%#+%,"'%$1,)4&035>%F
678%#+,'-*'-'+$'%G678#:%$0+%-'3.&,%#+%-04#;%5678%;'2-0;0,#)+%#+%,"'%$1,)4&035>%F
678%#+,'-*'-'+$'%#+()&('3%34'$#*#$%56783%<'#+2%,0-2',';%<1%3#+2&'H%3,-0+;';%
microRNAs#GmiRNAs:>%
F
I@JH@BK%)*%0&&%0+#50&%0+;%4&0+,%2'+'3%0-'%-'2.&0,';%<1%5#6783>%F
2.#!"#$"%)*%,"'%*)&&)L#+2%3,0,'5'+,3%$)--'$,&1%;'3$-#<'3%2'+'%-'2.&0,#)+%,"-).2"%678%
#+,'-*'-'+$'%G678#:9%
678%5)&'$.&'3%$0.3'%$&'0(02'%)*%;).<&'M%3,-0+;';%N78%)*%34'$#*#$%2'+'3>%8>
microRNAs#(miRNAs)#associated#with#a#RISC#enzyme#bind#to#complementary#
mRNAs.#
B.
O"'%6PQA%'+R15'%<#+;3%,)%0+;%$&'0('3%;).<&'M3,-0+;';%56783>%A>
678#%#+()&('3%<#+;#+2%)*%0%350&&%678%,)%0%,0-2',%2'+'%,)%#+0$,#(0,'%#,>%N>
678#%L)-/3%<1%5#6783%0*,'-%4-)$'33#+2%<1%;#$'-%G$.,3%)**%"0#-4#+%&))4:
6PQA%L#&&%;'2-0;'%)+'%)*%,"'%@%5678%3,-0+;3F
O"'%-'50#+#+2%3,-0+;%<#+;3%,)%,0-2',%$)54&'5'+,0-1%678F
N)L+-'2.&0,'3%0$,#(#,1%)*%2'+'3S%'+$);#+2%,"'%2'+'3%#+%T.'3,#)+F
6'2.&0,#+2%,"'%&#*',#5'%)*%0%4-),'#+%#3%0%L01%,)%$)+,-)&%#,3%0$,#)+3>%
U-),'#+3%#;'+,#*#';%*)-%<-'0/;)L+%0-'%)*,'+%&#+/';%,)%,"'%4)&14'4,#;'%Ubiquitin>%F
7'';%,)%$)+,0#+%;'2-0;#+2%'+R15'3%3)%,"'1%;)+V,%;'2-0;'%'('-1,"#+2F
U-),'03'3%#+%,"'%4-),'03)5'
O)%'+,'-%4-),'03)5'S%+'';%34'$#0&%0$$'33
○
O02%4-),'#+%L#,"%.<#T.#,#+%,"0,%*#,3%#+,)%0%4)-'%)+%,"'%4-),'03)5'
○
U-),'#+%L#&&%<'%;'&#('-';%,)%,"'%$'+,'-%)*%,"'%4-),'03)5'
○
F
O"'%protein–Ubiquitin#complex#,"'+%<#+;3%,)%0%$)54&'E%$0&&';% 0%proteasome>%F
O"'%4-),'#+%#3%$&'0(';%*-)5%,"'%Ubiquitin#0+;%,"-''%;#**'-'+,%proteases#digest#
the#protein>%
F
W('-0&&S%$'&&.&0-%4-),'#+%0$,#(#,#'3%;'4'+;%)+%-0,'3%)*%31+,"'3#3%0+;%-0,'3%)*%
;#2'3,#)+>%
F
X<#T.#,#+0,#)+%0+;%4-),'03)5'3%0-'%#+()&(';%#+%-'2.&0,#)+%,"'%&#*'340+%)*%
4-),'#+3%L#,"#+%,"'%$'&&
F
Y'0-+#+2%)<Z'$,#('3
!"#$%&'"()*"(+","%-.(/"$*-,&#/#(01($"..(#&+,-.&,+2(&,$.34&,+(3#"(01(#&+,-.(
)%-,#43$)&0,2(#"$0,4(/"##",+"%#2(-,4(#&+,-.(-/5.&1&$-)&0,(6&)*&,()*"($"..7(
87
90/5-%"()*"()60('%0-4($.-##"#(01(#&+,-.&,+(/0."$3."#(&,()*"('04:7(;%0-4.:(
$.-##&1&"4('-#"4(0,($*"/&$-.(/-<"357(=>?@(*:4%05*&.&$(0%(#/-..A*:4%05*0'&$B
C7
!"#$%&'"()*"(%0."(01()*"(#/-..(#&+,-.&,+(/0."$3."2(D&)%&$(0?&4"(=DEB2(&,()%&++"%&,+(
#/00)*(/3#$."(%".-?-)&0,(&,(-('.004FG"##".(6-..7(
H7
>?5.-&,()*"(/"$*-,&#/(01(-$)&0,(01(#)"%0&4(*0%/0,"#(350,()-%+")($"..#(3#&,+(
$0%)&#0.(-#(-,("?-/5."
I7
OL)%$)55.+#$0,#)+%313,'53
C+;)$-#+'%313,'5
[.50+%2-)L,"%")-5)+'%,"0,%'+,'-';%,"'%<&));%.3#+2%,"'%$#-$.&0,)-1%
313,'5%*)-%,-0+34)-,
○
F
7'-().3%313,'5
\03,'-
○
])-'%34'$#*#$
○
P+()&('%+'.-)+3%,"0,%'E,'+;%('-1%&)+2%4-)$'33'3%,)%-'0$"%34'$#*#$%,0-2',%
$'&&3
○
!"'+%3#2+0&%-'0$"'3%,"'%,'-5#+.3%)*%,"0,%$'&&S%0%+'.-),-0+35#,,'-%#3%
-'&'03';
○
F
?),"%"0('%$"'5#$0&3%0$,#+2%03%3#2+0&3
O'&&%$'&&3% ,)%;)%3)5',"#+2%0+;%2',%0%-'34)+3'%*-)5%,"'%+.$&'.3
○
Q#2+0&%#3%'E,'-+0&S%).,3#;'%,"'%$'&&
○
F
Outline:#Cell#Signaling#
[)L%$'&&3%$)55.+#$0,'^%3#2+0&%,-0+3;.$,#)+%0+;%@+;%5'33'+2'-3>%=>
Q50&&%3#2+0&#+2%5)&'$.&'3%'+,'-%,0-2',%$'&&3%0+;%<#+;%#+,-0$'&&.&0-%-'$'4,)-3>
7#,-#$_)E#;'%03%0%3#2+0&%
0>
Q,'-)#;%")-5)+0&%$.'3%
<>
@>
])3,%3#2+0&#+2%5)&'$.&'3%<#+;%$'&&_3.-*0$'%-'$'4,)-3>
`_4-),'#+%&#+/';%-'$'4,)-3
0>
P)+_$"0++'&%&#+/';%-'$'4,)-3%
<>
C+R15'%&#+/';%-'$'4,)-3%
$>
B>
87(J*"(+","%-.(/"$*-,&#/#(01($"..(#&+,-.&,+2(&,$.34&,+(3#"(01(#&+,-.()%-,#43$)&0,2(
#"$0,4(/"##",+"%#2(-,4(#&+,-.(-/5.&1&$-)&0,(6&)*&,()*"($"..7(
Signal#transduction##3%0+1%4-)$'33%<1%L"#$"%0%$'&&% $)+('-,3%)+'%/#+;%)*%3#2+0&%)-%
3,#5.&.3%#+,)%0+),"'->%
Signal#transduction##+()&('3%0%3'T.'+$'%)*%-'0$,#)+3%$0--#';%).,%<1%'+R15'3%
0+;%&#+/';%,"-).2"%3'$)+;%5'33'+2'-3
?#+;3%,)%0%-'$'4,)-%,)%3#2+0&%0+;%3,#5.&0,'3%0%-'34)+3'%#+%0%3#2+0&%,-0+3;.$,#)+%
40,"L01
W*,'+%+'';%,)%"044'+%#+%0%3,'4L#3'%50++'-
○
Q.$"%4-)$'33'3%,0/'%4&0$'%#+%03%&#,,&'%,#5'%03%0%5#&&#3'$)+;%)-%03%&)+2%03%0%*'L%
3'$)+;3>%
P+%50+1%,-0+3;.$,#)+%4-)$'33'3S%0+%#+$-'03#+2%+.5<'-%)*%'+R15'3%0+;%),"'-%
5)&'$.&'3%<'$)5'%'+202';%#+%,"'%'('+,3%,"0,%4-)$'';%*-)5%,"'%#+#,#0&%3,#5.&.3>%
O"'%$"0#+%)*%3,'43%#3%-'*'--';%,)%03%0%asignaling#cascade.”#
!"'-'%'0$"%'('+,%;'4'+;3%)+%,"'%4-'(#).3%'('+,
○
Second#messengers#0-'%5)&'$.&'3%,"0,%-'&01%3#2+0&3%-'$'#(';%0,%-'$'4,)-3%)+%,"'%$'&&%
3.-*0$'%
Q'$)+;%5'33'+2'-3%-'&01%3#2+0&3%b3.$"%03%,"'%0--#(0&%)*%4-),'#+%")-5)+'3S%
2-)L,"%*0$,)-3S%',$>%b,)%,0-2',%5)&'$.&'3%#+%,"'%$1,)3)&%0+;c)-%+.$&'.3>%
F
8;;#,#)+0&&1S%3'$)+;%5'33'+2'-3%3'-('%,)%amplify#the#strength#of#the#signal>%
7),%0%=^=%-'&0,#)+3"#43%)*%5)&'$.&'3%)*%3'$)+;%5'33'+2'-%0+;%5)&'$.&'3%
)*%3#2+0&
]0/'%0%&),%)*%5)&'$.&'3%)*%3'$)+;%5'33'+2'-%*)-%'('-1%)+'%3#2+0&
§
N)+'%3)%,"'%$'&&% 50/'3%0%-'34)+3'
§
A'&&%L#&&%4'-*)-5%0+%044-)4-#0,'%0$,#)+%;','-5#+';%<1%,"'%3#2+0&%#,%
-'$'#('3
§
○
F
CE054&'3%)*%3'$)+;%5'33'+2'-3%#+$&.;'%$1$&#$% +.$&'),#;'3%G'>2>S%$1$&#$%8]U%0+;%
$1$&#$%`]U:%0+;%A0&$#.5%#)+3%GA0@d:>%
7)+'%)*%,"'5%0-'%4-),'#+3
○
\)-53%3'$)+;%5'33'+2'-3
○
F
P54)-,0+,^
6'T.#-';%$)54)+'+,3%)*%40-,#$.&0-%40,"L013
○
854&#*1%3,-'+2,"%)*%3#2+0&3
○
F
C7(>?)%-$"..3.-%(#&+,-.(/0."$3."#(1-..(&,)0(0,"(01()60($.-##"#(
O"'%350&&'-%$&033%)*%3#2+0&3%$)+3#3,3%)*%5)&'$.&'3%,"0,%0-'%small%)-%hydrophobic%
'+).2"%,)%3&#4%'03#&1%,"-).2"%,"'%4&0350%5'5<-0+'%0+;%0$,#(0,'%#+,-0$'&&.&0-%
'+R15'3%)-%<#+;%,)%#+,-0$'&&.&0-% -'$'4,)-3%,)%-'2.&0,'%2'+'%'E4-'33#)+>%G*)-%
'>2>%e7#,-#$%WE#;'%0+;%A)-,#3)&:%
?'"0('%,"'%305'%L01%#+%3#2+0&#+2%40,"L0130>
U033%4&0350%5'5<-0+'%0+;%-'$'4,)-%,"0,%;','$,3%,"'#-%4-'3'+$'%#3%#+3#;'%
,"'%$'&&
<>
=>
O"'%&0-2'3,%$&033%)*%3#2+0&3%$)+3#3,3%)*%5)&'$.&'3%)oo%hydrophilic%,)%$-)33%,"'%
4&0350%5'5<-0+'%)*%,"'%,0-2',%$'&&>%O"'1%-'&1%)+%$'&&%3.-*0$'%-'$'4,)-3%,)%-'&01%
5'3302'3%#+,)%,"'%$'&&>%G*)-%'>2>%eP+3.&#+:%
P+3.&#+%#3%0%4-),'#+%")-5)+'%50;'%<1%,"'%40+$-'03
`)'3%,"-).2"%,"'%<&));%,)%$)55.+#$0,'%,"'%$'&&3% L"'+%,)%0<3)-<%
2&.$)3'%*-)5%,"'%<&));
#>
0>
8$,3%,"-).2"%$'&&%3.-*0$'%-'$'4,)-3<>
@>
H7(>,40)*".&-.($"..#(-%"()*"(#5"$&-.&K"42(1.-))","4("5&)*".&-.($"..#()*-)(.&,"("G"%:('.004(
G"##".
6';%<&));%$'&&%#+%0-,'-1%&'0;3%1).%,)%$)&&'$,%0%'+;),"'&#.5%$'&&3%,"0,%&#+'%,"'%
#+,'-#)-%)*%,"'%0-,'-1
N#05','-%#+*&.'+$'3%<&));%*&)L
○
A0+%$)+3,-#$,%35)),"%5.3$&'%)-%-'&0E'3
!"'+%-'&0E';S%,"'%#+,'-#)-%)*%,"'%0-,'-1%2',3%<#22'-%0+;%4-)5),'3%
<&));%*&)L
§
○
\#<-)<&03,%$'&&3%$-'0,'3%,#33.'%,"0,%")&;3%'('-1,"#+2%,)2',"'-
○
F
7#,-#$%)E#;'%G7W:%#3%0%;#33)&(';%203%,"0,%;#**.3'3%).,%)*%'+;),"'&#0&%$'&&3%f%'+,'-3%
+'#2"<)-#+2%35)),"%5.3$&'%$'&&3>%
P54)-,0+,%#+%;','-5#+#+2%,)%L"0,%;'2-''%).-%(03$.&0-%#3%$)+3,-#$,';%)-%-'&0E';F
7#,-#$%)E#;'%<#+;3%,)%,"'%'+R15'%Guanylyl#cyclase,#3,#5.&0,#+2%*)-50,#)+%)*%
$`]U%
X3'3%0-2#+#+'%,)%<-'0/%;)L+
○
F
The#gas#nitric#oxide#(NO)#causes#the#relaxation#of#smooth#muscles#of#the#blood#
vessels.#
Q50&&%3#2+0&%50;'%<1%'+;),"'&#.5%,)%$)55.+#$0,'%,)%35)),"%5.3$&'%0+;%
-'2.&0,'%<&));%*&)L
○
8$',1&$")&#+'%$0.3'3%#+$-'03';%A0@d%&'('&3%#+%,"'%'+;),"'&#0&%$'&&3S%L"#$"%
$0.3'3%,"'%0$,#(0,#)+%)*%NO#synthaseS%,"'%'+R15'%,"0,%50/'3%NO>%
X3'3%0-2#+#+'%03%0%3.<3,-0,'%,)%50/'%7W
§
A0,0<)&#$%-'0$,#)+%L"'-'%7W%#3%-'&'03';%*-)5%3.<3,-0,'%0-2#+#+'
§
○
NO#;#**.3'3%-04#;&1%*-)5%,"'%'+;),"'&#0&%$'&&3%,)%,"'%+'0-<1%35)),"%
5.3$&'%$'&&3>%
A0.3'3%#+$-'03'%)*%$`]U%$)+$'+,-0,#)+
§
○
P+%,"'%35)),"%5.3$&'%$'&&3S%NO#0$,#(0,'3%,"'%'+R15'%guanylyl#cyclaseS%
L"#$"%3,#5.&0,'3%,"'%*)-50,#)+%)*%$`]U>%
8$,#(0,'3%40,"L01%,"0,%$0.3'3%35)),"%5.3$&'%$'&&%,)%-'&0E
§
○
F
4.#[)L%;)'3%+#,-#$%)E#;'%G7W:%'+,'-%35)),"%5.3$&'%$'&&39%7W^%
$-)33'3%,"'%35)),"%5.3$&'%$'&&% 4&0350%5'5<-0+'%,"-).2"%#)+%$"0++'&3>%8>
$-)33'3%,"'%35)),"%5.3$&'%$'&&% 4&0350%5'5<-0+'%,"-).2"%$"0++'&3%$0&&';%
8T.04)-#+3>%
?>
diffuses#directly#across#the#smooth#muscle#cell#plasma#membrane.#C.
$0++),%'+,'-%35)),"%5.3$&'%$'&&3>%N>
7'';%,)%;'2-0;'%3'$)+;%5'33'+2'-
P*%$`]U%3,01';%,"'-'%*)-'('-S%1).%$0+V,%-'2.&0,'%<&));%*&)L%,)%,0-2',%,#33.'%0+;%
0&L013%"0('%0%"#2"%&'('&%)*%*&)L
F
Q5)),"%5.3$&'%L#&&%)+&1%<'%.3'*.&%#*%)+&1%3)5'%$)+;#,#)+3S%1).%$0+%4-)(#;'%
<&));%*&)L%,)%0%40-,#$.&0-%,#33.'%0+;%+),%,"'%0+),"'-
F
g#02-0%4-)5),'3%35)),"%5.3$&'%-'&0E0,#)+%#+%,"'%(03$.&0,.-'%
g#02-0%'+"0+$'3%,"'%'**'$,3%)*%7W%<1%inhibiting#the#enzyme#
Phosphodiesterase#(PDE)#,"0,%+)-50&&1%<-'0/3%;)L+%$`]US%4-)&)+2#+2%
,"'%7W%3#2+0&S%,".3%4-)&)+2#+2%4'+#&'%'-'$,#)+>%
UNC3%+)-50&&1%<-'0/%;)L+%3'$)+;%5'33'+2'-3
§
\)$.3'3%)+%0%-'4-);.$,#('%,#33.'
§
X3.0&&1%<-'0/3%;)L+%$`]U%#+%4'+0&%35)),"%5.3$&'3
§
○
W-#2#+0&&1%.3';%#+%4')4&'%L#,"%"'0-,%;#3'03'
P+0;('-,'+,%;#3$)('-1
§
○
P+"#<#,%UNC%0+;%4-)5),'%$`]U%3#2+0&#+2%0+;%<&));%*&)L
○
F
5.#P+;#(#;.0&3%4)33'33#+2%0%5.,0,#)+%#+%,"'%2'+'%'+$);#+2%,"'%'+R15'S%7#,-#$%WE#;'%
Q1+,"03'%G7WQ:%)('-4-);.$'%,"'%3#2+0&#+2%5)&'$.&'S%7#,-#$%WE#;'%G7W:%-'3.&,#+2%#+%&)L%
<&));%4-'33.-'>%W+%0%$'&&.&0-%&'('&S%L"#$"%)+'%)*%,"'%*)&&)L#+2%L).&;%<'%"'&4*.&%#+%
-';.$#+2%,"'%"0-5*.&%'**'$,3%)*%,"#3%7WQ%2'+'%5.,0,#)+9%
P+$-'03#+2%,"'%05).+,%)*%$1$&#$%2.0+)3#+'%5)+)4")34"0,'%G$`]U:%#+%35)),"%
5.3$&'%$'&&3>%
8&-'0;1%"0('%,))%5.$"%$`]U
○
8>
Increasing#the#activity#of#the#enzyme#phosphodiesterase#in#smooth#muscle#
cells.#
B.
P+$-'03#+2%,"'%8$',1&$")&#+'%3#2+0&%3'+,%,)%'+;),"'&#0&%$'&&3>%
8$',1&$")&#+'%3,#5.&0,'3%,"'%7W%31+,"03'%'+R15'%,"0,%L'%0&-'0;1%"0('%
,))%5.$"%)*
○
A>
P+"#<#,#+2%0$,#(0,#)+%)*%,"'%8$',1&$")&#+'%-'$'4,)-3%#+%'+;),"'&#0&%$'&&3>%
Q").&;%L)-/%<.,%,"'%#33.'%#3%,"0,%,"'%'+R15'%#3%<'#+2%*)-5';%#+%0+%
.+.3.0&%3,0,'%0+;%#3%)+%#+;'4'+;'+,%)*%0$',1&$")&#+'
○
P*%1).%-'5)('%,"'%0$',1&$")&#+'S%#,%L)+V,%0**'$,%,"'%)('-0$,#('%'+R15'
`'+'%5.,0,#)+%$0.3'3%,"'%.4-'2.&0,#)+S%+),%3)5',"#+2%'&3'%#+%,"'%
-'0$,#)+3
§
○
N>
N'$-'03#+2%,"'%0$,#(#,1%)*%,"'%'+R15'%4")34");#'3,'-03'%#+%'+;),"'&#0&%$'&&3>%C>
].,0,#)+%#+%7WQ%'E4-'33';%#+%'+;),"'&#0
7)-50&&1%4-);.$'3%7W%,)%3,#5.&0,'%35)),"%5.3$&'%$'&&%-'&0E0,#)+F
['-'S%"0('%0+%0&&'&'% ,"0,%$0.3'3%7W%,)%0&L013%<'%)+%0+;%#3%)('-4-);.$';F
!"'+%35)),"%5.3$&'%#3%0&L013%-'&0E';S%,"'-'V3%'--)+').3%<&));%*&)LF
X4-'2.&0,'%,"'%0$,#(#,1%)*%UNC%$'&&3%,)%<-'0/%;)L+%'E$'33%,)%$`]U%,)%$).+,'-0$,%
'**'$,%)*%,"#3%5.,0,#)+
F
I7(L:4%05*0'&$(#)"%0&4(*0%/0,"#($%0##()*"(5.-#/-(/"/'%-,"(01()*"()-%+")($"..
Q,'-)#;%")-5)+'3
N'-#(';%*-)5%$")&'3,'-)&%
○
A)-,#3)&%#+"#<#,3%,"'%#55.+'%313,'5
○
F
Q,'-)#;%")-5)+'3%0&&%4033%,"-).2"%,"'%4&0350%5'5<-0+'%)*%,"'%,0-2',%$'&&F
P+%,"'%$'&&S%,"'%")-5)+'3%<#+;%,)%0+;%0$,#(0,'%-'$'4,)-3%*).+;%#+%,"'%$1,)4&035%
)-%,"'%+.$&'.3
F
X4)+%0$,#(0,#)+S%,"'%")-5)+'%-'$'4,)-3%0-'%$040<&'%)*%-'2.&0,#+2%2'+'%
,-0+3$-#4,#)+
F
Cell$Signaling
])+;01S%84-#&%@BS%@J=h =@^Ji%U]
Unlock document

This preview shows pages 1-3 of the document.
Unlock all 9 pages and 3 million more documents.

Already have an account? Log in

Document Summary

5: feedback control, translational control, transcriptional control, posttranscriptional control, posttranslational control. Noncoding rnas are involved in regulating gene expression. Rna interference can result in rapid mrna degradation in the cytoplasm. Rna interference (rnai) can result in rapid mrna degradation in the cytoplasm. Rna interference involves specific mrnas being targeted by single< stranded micrornas (mirnas). Rna molecules cause cleavage of double> stranded dna of specific genes. micrornas (mirnas) associated with a risc enzyme bind to complementary mrnas. The risc enzyme binds to and cleaves double>stranded mrnas. Rnai involves binding of a small rna to a target gene to inactivate it. Rnai works by mirnas after processing by dicer (cuts off hairpin loop) Risc will degrade one of the 2 mrna strands. The remaining strand binds to target complementary rna. Downregulates activity of genes, encoding the genes in question. Regulating the lifetime of a protein is a way to control its actions.

Get access

Grade+20% off
$8 USD/m$10 USD/m
Billed $96 USD annually
Grade+
Homework Help
Study Guides
Textbook Solutions
Class Notes
Textbook Notes
Booster Class
40 Verified Answers
Class+
$8 USD/m
Billed $96 USD annually
Class+
Homework Help
Study Guides
Textbook Solutions
Class Notes
Textbook Notes
Booster Class
30 Verified Answers

Related Documents

BIOL 142 Lecture Notes - Lecture 27: Regulatory Sequence, Tata Box, Rna Splicing
bluemosquito338
BIOL 142 Lecture Notes - Lecture 23: Replica Plating, Microrna, Gene Expression
bluemosquito338
BIOL 142 Lecture Notes - Lecture 8: Replica Plating, Lac Operon, Galactose
raynagorstein